Nanoemulsion vaccines

Details Nanoemulsion vaccines Nanoemulsion vaccines

2008-01-01

2008-01-01

Campell, Bruce (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

Reexamination Certificate

active

10162970

ABSTRACT:
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.

REFERENCES:
patent: 4481188 (1984-11-01), Apontoweil et al.
patent: 4895454 (1990-01-01), Kammleiter et al.
patent: 5103497 (1992-04-01), Hicks
patent: 5510104 (1996-04-01), Allen
patent: 5547677 (1996-08-01), Wright
patent: 5549901 (1996-08-01), Wright
patent: 5618840 (1997-04-01), Wright
patent: 5662957 (1997-09-01), Wright
patent: 5700679 (1997-12-01), Wright
patent: 5942237 (1999-08-01), Gizurarson et al.
patent: 5961970 (1999-10-01), Lowell et al.
patent: 6015832 (2000-01-01), Baker et al.
patent: 6350784 (2002-02-01), Squires
patent: 6506803 (2003-01-01), Baker et al.
patent: 6565873 (2003-05-01), Shefer et al.
patent: 2002/0045667 (2002-04-01), Baker et al.
Fields. Fields Virology. Lippincott Williams & Wilkins Publishers; Aug. 2001, p. 1555.
Cox et al. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology. vol. 59, p. 1-15.
Paul. Fundamental Immunology. Lippincott Williams & Wilkins Publishers; 5th edition Sep. 2003, p. 1353.
Tumpey et al. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. Journal of virology, Jun. 2001, vol. 75, No. 11, 5141-5150.
Donovan et al. Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions. Antiviral Chemistry and Chemotherapy, 2000, vol. 11, pp. 41-49.
Bielinska et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects againstBacillus anthracisspore challenge. Infection and Immunity. Aug. 2007, vol. 75, No. 8, 4020-4029.
Richter and Kipp, Curr Top Microbiol Immunol 240:159-76 [1999].
Ruedl and Wolf, Int. Arch. Immunol., 108:334 [1995].
Mor et al., Trends Micrbiol 6:449-53 [1998].
McMichael, Curr. Top. Microbiol. Immunol. 189:75 [1994].
Sercarz et al., Anu Rev Immunol 11:729 [1993].
Perreault et al., Immunol Today 19:69 [1998].
Silins et al., J Exp Med 184:1815 [1996].
Steven et al., J Exp Med 184:1801 [1996].
Tremblay et al., Transplantation 58:59 [1994].
Russell, Clin. Micro. 3; 99 [1990].
Burdon and Wende, J Infect. Diseas. 170(2):224-34 [1960].
Lamanna and Jones, J. Bact. 85:532 [1963].
Burdon et al., J Infect. Diseas. 117:307 [1967].
Drobniewski, Clin. microbio. Rev. 6:324 [1993].
Fritz et al., Lab. Invest. 73:691 [1995].
Hamouda et al., J. Infect Dis., 180:1939 [1999].
Hamouda and Baker, J. Appl. Microbiol., 89:397 [2000].
Eriksson et al., Blood Coagulation and Fibtinolysis 5 (Suppl. 3):S37-S44 [1994].
Maha and Igarashi, Southeast Asian J. Trop. Med. Pub. Health 28:718 [1997].
Portocala et al., Virologie 27:261 [1976].
Horowitz et al., Blood 79:826 [1992].
Hills, J. Gen. Micro. 4:38 [1950].
Halvorson and Church, Bacteriol Rev. 21:112 [1957].
Yanagita, Arch Mikrobiol 26:329 [1957].
Brown et al., J. Bact., 75:499 [1958].
Stevens et al., Antimicrob. Agents Chemother., 31:312 [1987].
Stevens et al., J. Infect. Dis., 155:220 [1987].
Alttemeier et al., Surgery, 28:621 [1950].
Sandusky et al., Surgery, 28:632 [1950].
Butterton et al., Infect. Immun., 64:4373 [1996].
Levine et al., Microbiol. Rev., 47:510 [1983].
Finkelstein et al., J. Infect. Dis., 114:203 [1964].
Freter, J. Exp. Med., 104:411 [1956].
Freter, J. Infect. Dis., 97:57 [1955].
Formal et al., J. Bact., 85:119 [1963].
LaBrec et al., J. Bact. 88:1503 [1964].
Takeuchi et al., Am. J. Pathol., 47:1011 [1965].
Naughton et al., J. Appl. Bact., 81:651 [1996].
Carter and Collins, J. Exp. Med., 139:1189 [1974].
Collins, Infect. Immun., 5:191 [1972].
Collins and Carter, Infect. Immun., 6:451 [1972].
Jacoby et al., Exp. Gerontol., 29:89 [1994].
Massion et al., Am. J. Respir. Cell Mol. Biol. 9:361 [1993].
Castleman et al., Am. J. Path., 129:277 [1987].
Castleman, Am. J. Vet. Res., 44:1024 [1983].
Mims and Murphy, Am. J. Path., 70:315 [1973].
Johnson et al., J. Infect. Dis., 125:257 [1972].
Johnson, Am. J. Path., 46:929 [1965].
Welkos et al., Infect Immun. 51:795 [1986].
Welkos and Friedlander, Microb Pathog 5:127 [1988].
Karaivanova and Spiro, Biochem J. 329(Pt 3):511 [1998].
Mammen et al., J Med Chem 38:4179 [1995].

Affiliated with

Also associated with

Rating

Nanoemulsion vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nanoemulsion vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoemulsion vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3907159